ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Calypte Receives African Order For Aware(TM) HIV-1/2 Oral Fluid Rapid Tests
Calypte Biomedical
Corporation (Amex: HIV) (the "Company"), medical diagnostic tests
manufacturer for the professional point of care (PRO) and over the counter
(OTC) segments of the market for the detection of antibodies to the human
immunodeficiency virus (HIV), announced today that it has received an
initial order for 35,500 units of its Aware(TM) HIV-1/2 oral fluid rapid
test. This initial order has been placed through Gennaria Comercio
International Lda on behalf of MineSeeker Foundation and will be sold
through Calypte's exclusive distributors in Africa once final destinations
are known. Calypte currently has approval to sell its rapid oral fluid test
in South Africa and Kenya. Based on Calypte's communications with
MineSeeker, this is the first firm order of a series of orders totaling 1.0
million tests that MineSeeker intends placing with Calypte over the next 12
months.
Gennaria represents several humanitarian organizations, including
MineSeeker, which plans to launch a large-scale HIV testing initiative in
Africa beginning this September.
Nelson Mandela said: "As a patron of MineSeeker, I totally support the
AIDS test initiative. The tests will remove the fear of many people who
believe they may be infected and who are nervous about blood testing. Fear
is a terrible affliction, whether it is the fear of treading on a mine or
the fear not knowing if you are HIV positive."
Roger I. Gale, Calypte's Chairman and Chief Executive Officer
commented, "We have long believed we have been developing an effective
solution in the battle against HIV/AIDS with a non-invasive rapid
diagnostic test. Now that we are receiving approvals in HIV-stricken areas
in Sub-Saharan Africa, we are targeting humanitarian organizations that
want to make significant contributions in the fight against AIDS."
Mr. Mike Kendrick, founder of MineSeeker, stated, "The intended first
order of 1 million tests is part of a larger MineSeeker initiative to
deliver 5 million HIV oral fluid rapid tests to Africa. The purchase of the
initial 1 million Aware(TM) HIV-1/2 oral swab rapid tests will be donated
to NGOs for distribution in the field or sold, at cost."
Mr. Kendrick continued, "While the primary objective of MineSeeker is
the eradication of land mines, we are also committed to the regeneration of
the local communities. Without that, the clearance of mines is only part of
the answer. Land will be returned to the people to grow food and a foster
management program installed to help re-establish themselves. This will
mean growing good quality crops that will lift the natural immunity system
-- particularly helping AIDS sufferers. The introduction of the Aware(TM)
product will help re-build the confidence of these communities."
About MineSeeker Foundation:
The MineSeeker Foundation ( http://www.mineseeker.com ) is primarily involved
with the removal of land mines. The foundation has a new initiative, the
'Sole of Africa' initiative, which includes returning mine free land back
to agriculture and an educational and empowerment program that trains local
people to farm and vocational training for people unable to find work,
including land mine and AIDS victims.
The MineSeeker Foundation Patrons include Nelson Mandela, Sir Richard
Branson, Queen Noor of Jordon, Graca Machel, John Paul Dejoria and Brad
Pitt. The Foundation is supported by other leading NGOs including 'Feed the
Children', The International Youth Foundation and The Salvation Army.
About Calypte Biomedical:
Calypte Biomedical Corporation (http://www.calypte.com) is a U.S.-based
healthcare company focused on the development and commercialization of
diagnostic testing products for the detection of sexually transmitted
diseases such as the HIV-1 BED Incidence EIA and new diagnostic test
products for the rapid detection of HIV and other sexually transmitted
diseases, several of which do not require blood samples. Calypte believes
there is a significant need for rapid detection of such diseases globally
to control their proliferation, particularly in developing countries, which
lack the medical infrastructure to support laboratory-based testing.
Calypte believes that testing for HIV and other sexually transmitted
infectious diseases may make important contributions to public health, and
could increase the likelihood of treating those with undetected HIV and
other sexually transmitted diseases.
Statements in this press release that are not historical facts are
forward-looking statements within the meaning of the Securities Act of
1933, as amended. Those statements include statements regarding the intent,
belief or current expectations of the Company and its management. Such
statements reflect management's current views, are based on certain
assumptions and involve risks and uncertainties. Actual results, events, or
performance may differ materially from the above forward-looking statements
due to a number of important factors, and will be dependent upon a variety
of factors, including, but not limited to, the Company's ability to obtain
additional financing, if and as needed, and access funds from its existing
financing arrangements that will allow it to continue its current and
future operations and whether demand for its test products in domestic and
international markets will generate sufficient revenues to achieve positive
cash flow and profitability. The Company undertakes no obligation to
publicly update these forward-looking statements to reflect events or
circumstances that occur after the date hereof or to reflect any change in
the Company's expectations with regard to these forward-looking statements
or the occurrence of unanticipated events. Factors that may impact the
Company's success are more fully disclosed in the Company's most recent
public filings with the U.S. Securities and Exchange Commission ("SEC"),
including its annual report on Form 10-KSB for the year ended December 31,
2005 and its subsequent filings with the SEC.
Calypte Biomedical
http://www.calypte.com
Primeºte Calypte africane pentru Conºtient (TM) HIV-1 / 2 Orala fluidelor testele rapide - Calypte Receives African Order For Aware(TM) HIV-1/2 Oral Fluid Rapid Tests - articole medicale engleza - startsanatate